High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors

被引：8
|
作者：
Sturt, NJH [1 ]
Phillips, RKS
Clark, SK
机构：
[1] St Marks Hosp, Colorectal Canc Unit, Polyposis Registry, Harrow, Middx, England
[2] Royal London Hosp Barts & London NHS Trust, Ctr Acad Surg, London, England
来源：
CANCER | 2004年 / 101卷 / 03期
关键词：
D O I：
10.1002/cncr.20416
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：652 / 652
页数：1
相关论文
共 50 条
  • [21] High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
    Ychou, M
    Raoul, JL
    Desseigne, F
    Borel, C
    Caroli-Bosc, FX
    Jacob, JH
    Seitz, JF
    Kramar, A
    Hua, A
    Lefebvre, P
    Couteau, C
    Merrouche, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (05) : 383 - 391
  • [22] High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer
    M. Ychou
    J. Raoul
    F. Desseigne
    C. Borel
    F. Caroli-Bosc
    J. Jacob
    J. Seitz
    A. Kramar
    A. Hua
    P. Lefebvre
    C. Couteau
    Y. Merrouche
    Cancer Chemotherapy and Pharmacology, 2002, 50 : 383 - 391
  • [23] Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP
    Gomez-Almaguer, David
    Herrera-Rojas, Miguel Angel
    Gomez-de Leon, Andres
    Cantu-Rodriguez, Olga Graciela
    Gutierrez-Aguirre, Cesar H.
    Jaime-Perez, Jose Carlos
    Tarin-Arzaga, Luz C.
    Ruiz-Arguelles, Guillermo J.
    Hernandez-Reyes, Jesus
    BLOOD, 2013, 122 (21)
  • [24] First-line high-dose chemotherapy for 'poor risk' metastatic non-seminomatous testicular germ cell tumors
    Bokemeyer, C
    Harstrick, A
    Beyer, J
    Metzner, B
    Rüther, U
    Hartmann, JT
    Holstein, K
    Derigs, HG
    de Wit, R
    Casper, J
    Schöffski, P
    Kührer, I
    Illiger, HJ
    Kempf, B
    Reichle, A
    Föller, A
    Hossfeld, DK
    Fischer, JT
    Berdel, W
    Gerhartz, H
    Kirchner, H
    Pflüger, K
    Ostermann, H
    Kanz, L
    Schmoll, HJ
    ONKOLOGIE, 1998, 21 : 23 - 25
  • [25] Clinical Outcome of Tamoxifen and Sulindac for Desmoid Tumors in Adults: A Phase II Single Institution Experience
    Anter, Abeer Hussien
    Abdel-Latif, Rasha Mohamed
    MIDDLE EAST JOURNAL OF CANCER, 2019, 10 (02) : 125 - 131
  • [26] Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with immune thrombocytopenia
    Aydin, Kaniye
    Gurkan, Emel
    CUKUROVA MEDICAL JOURNAL, 2022, 47 (02): : 715 - 721
  • [27] Efficacy and safety of first-line high-dose cytarabine in patients with primary CNS lymphoma ineligible for high-dose methotrexate: A case series
    Zeremski, Vanja
    Haage, Tobias Ronny
    Mougiakakos, Dimitrios
    NEURO-ONCOLOGY PRACTICE, 2024,
  • [28] High-dose chemotherapy with transplant yields encouraging outcomes as first-line treatment for patients with high-risk aggressive lymphoma
    不详
    CLINICAL LYMPHOMA, 2003, 3 (04): : 205 - 206
  • [29] A HIGH-DOSE TAMOXIFEN REGIMEN
    SHAIKH, NA
    GHILCHIK, MW
    BRITISH JOURNAL OF CANCER, 1987, 56 (06) : 870 - 870
  • [30] Evaluation of the outcome of long-term conservative treatment with sulindac and high-dose selective estrogen receptor modulators (SERMs) for sporadic and FAP-associated Desmoid tumors.
    Moeslein, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 124 - 125
12345